Tag Archives: Drug

John Giles, Jr., Director, Covance Market Access Services

John GilesJohn is a Director in Managed Market Services and leads the business development in Covance Managed Market Services business. He has been in various roles for 25 years in the healthcare industry, specializing in a wide variety of data solutions, account management, analytics and enterprise wide systems. 

He has worked for Roche and Johnson & Johnson in sales and marketing, contracting and sales operations. Before joining Covance, John was an Account Executive for IMS Health selling the portfolio of products and services. At IMS Health, John worked closely with Fortune 50 companies to help create marketing strategies and create solutions to wide variety of issues.

1. Why did you decide to do a webinar with us?

BRW is the gold standard of webinar vendors.

2. What will the audience gain from attending your webinar?

A better understanding of the 340B Program as it continues to evolve and raise concerns.

3. How did you get into the industry and what do you most enjoy about your role?

I started in the pharma industry in 1991 with Roche as a sales rep, then moved into management in sales operations in various roles on both sides , manufacturing and vendor.  What I enjoy most about my role is guiding clients through the complex healthcare issues that exist and continue to grow even more complex.

4. What are you hoping to achieve in the future in your personal and professional life?

To continue to be a constant learner. Life and the market are always evolving. I want to continue to identify the patterns and trends and stay current with the technology as the healthcare system undergoes rapid transformation.

5. What would someone be surprised to know about you? 

I have been skydiving and scuba diving.

John will be presenting Covance’s webinar ‘Challenges of Complying with 340B Program‘ with Steve Madina, Vice President, Covance Market Access Services on the 30th April at 1pm New York/6pm London. You can register for the webinar here


Dr. Peter Klaffenbach, Head of Pharmaceutical Development, LTS Lohmann Therapy Systems

Peter Klaffenbach
Dr. Peter Klaffenbach has been in transdermal drug delivery systems development for over 20 years and is now in charge of pharmaceutical development of LTS. Prior to joining LTS, Peter was managing director at the German drug delivery company Labtec (now tesa-Labtec) and head of pharmaceutical development at 3M drug delivery in Germany.

1. Why did you decide to do a webinar with Business Review Webinars?

Actually, my marketing department thought that a webinar could be the right platform to reach an interested audience of professionals to share our knowledge of transdermal drug delivery. Patch technology is still a niche – conferences are rare and expensive. Webinars represent a modern and effective way to discuss these kinds of topics with the industry.

2. What are you looking forward to explaining to the audience?

I’m looking forward to share our vision. That is that transdermal systems are not only an excellent option for lifecycle management of established APIs, but the technology should also be considered very early in NCE development and considered as a first line dosage form.

3. What is the ideal outcome you would like from doing the webinar?

If some of the attendees would consider a patch as an alternative to a tablet as part of the initial drug product development, this would be a great outcome.

4. Where is your favourite place in the world and why?

Anywhere, as long it is underwater. Why? Because underwater we need to refocus our senses and we can enjoy life in three dimensions.

5. What motivates you?

To help patients to deal with their problems a little more easily by providing solutions that meet their needs.

Peter will be presenting his webinar ‘Transdermal Drug Delivery: Is it feasible for your drug?‘ on the 25th November at 10am New York/3pm London. Click here to read more and register.


Stephen Tindal, Director, Formulation and Site R&D Lead, Catalent

Stephen TindalStephen holds a bachelors degree in Chemistry and Analytical Science from Loughborough University, UK. He has worked in softgel R&D for 27 years and has broad expertise in the technology. Stephen specializes in root cause investigation, technology innovation, gelatin innovation, customer liason and supporting business development. Stephen is part of Catalent’s R&D Team at the Company Headquarters in Somerset, New Jersey.

1. Why did you decide to do a webinar with us?

Catalent is a big company with a wide range of capabilities.  It may be difficult for people to truly understand our capabilities based on published information.  It’s important when describing enabling technologies to get into more detail.  This is the only way to match a technology to a specific need.

2. How do you prepare yourself when presenting to a live audience?

I like to make sure I fully understand the message I’m trying to deliver.  I feel more relaxed if I know the subject really well.

3. What are some of the best moments of your career?

The best moment was when I found what I was good at and realized I wanted to do it forever.

4. If you could have a super power, what would it be and why?

Flying.  Just for the thrill.

5. What is your favourite flavour of ice-cream?


You can register now for Catalent’s webinar ‘ Optimize Your Oral Drug Development Pathway – Faster to Market’ taking place on the 30th October at 11am  New York/3pm London.